Compare BNTC & USNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTC | USNA |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 362.9M |
| IPO Year | N/A | 1996 |
| Metric | BNTC | USNA |
|---|---|---|
| Price | $12.91 | $20.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $26.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 230.7K | 168.4K |
| Earning Date | 11-14-2025 | 10-22-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.90 |
| Revenue | N/A | ★ $912,670,000.00 |
| Revenue This Year | N/A | $9.87 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.32 |
| Revenue Growth | N/A | ★ 5.88 |
| 52 Week Low | $9.70 | $18.48 |
| 52 Week High | $17.15 | $38.85 |
| Indicator | BNTC | USNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 56.51 |
| Support Level | $12.78 | $19.33 |
| Resistance Level | $13.68 | $20.40 |
| Average True Range (ATR) | 0.75 | 0.61 |
| MACD | 0.09 | 0.26 |
| Stochastic Oscillator | 59.35 | 92.25 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.